AnaptysBio, Inc.
ANABDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ANAB Earnings Report
EPS Est: $-0.22 | FQ end 2026-06
How ANAB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rosnilimab | Phase 2 | Rheumatoid Arthritis | - | - |
Etokimab | Phase 2 | Chronic Rhinosinusitis | - | - |
Rheumatoid Arthritis
1 drug in this indication
Chronic Rhinosinusitis
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AnaptysBio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in AnaptysBio, Inc.'s (ANAB) pipeline across Phase 2. Its lead program is Rosnilimab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AnaptysBio, Inc.'s next FDA catalyst?→
AnaptysBio, Inc.'s (ANAB) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANAB biotech catalysts?→
Add ANAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AnaptysBio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.